Boston Scientific Stock
Boston Scientific Stock
Pros and Cons of Boston Scientific in the next few years
Pros
Cons
Performance of Boston Scientific vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Boston Scientific | -0.780% | -1.550% | 2.651% | 34.963% | 23.445% | 85.999% | 103.460% |
| QuidelOrtho Corp. | -0.550% | -10.448% | -20.160% | -56.385% | -46.918% | -66.512% | - |
| Illumina Inc. | -0.340% | -10.000% | -8.406% | -47.323% | -14.693% | -67.071% | -61.429% |
| Waters Corp. | -1.750% | -11.495% | -13.625% | -1.986% | -8.477% | 9.683% | 31.026% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Boston Scientific Corporation (NYSE: BSX) is a prominent player in the healthcare equipment and supplies industry. A review of its financial statements in recent years paints an interesting picture of the company's growth and stability. Initially, it seems that Boston Scientific has experienced a robust increase in total assets and revenue, as indicated in the balance sheet and income statements, which is generally a positive sign for any business. However, a detailed analysis of the company's financials is necessary to better understand its financial health and identify any possible concerns.
*Pros: *
Growth in Total Assets and Total Revenue: Boston Scientific's total assets have been consistently growing year-over-year since 2020, and its total revenue increased from €9.91 billion in 2020 to $12.68 billion in 2022. This growth is indicative of the company's ability to generate business in its niche market and points to a healthy expansion of its operations.
Comments